Glimepiride + Pioglitazone + Metformin PCD Pharma Franchise

Brand Name

GLISOT 1-PM Tablet (Bilayered)

Composition

Glimepiride 1mg, Pioglitazone 15mg & Metformin 500mg(PR)

Therapeutic Use

ANTIDIABETICS

Size

10 x 15

Verified Exporter

Verified Seller

Trusted Pharma

Description

GLISOT 1-PM Tablet (Bilayered) contains Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg prolonged release (PR). This triple-combination antidiabetic formulation contains medicines from three different classes that work through complementary mechanisms to help manage blood glucose levels in adults with type 2 diabetes mellitus when prescribed by a qualified healthcare professional.

Glimepiride is a sulfonylurea that stimulates insulin release from the pancreas. Pioglitazone is a thiazolidinedione that improves insulin sensitivity, while Metformin primarily reduces glucose production in the liver and improves the body’s response to insulin. Treatment should be individualized and accompanied by appropriate diet, physical activity and regular blood glucose monitoring.

CardianCare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business partners. Businesses searching for a Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR Tablets manufacturer India can enquire about current product availability, approved specifications and applicable quality documentation.

For procurement teams evaluating a Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR Tablets manufacturer and supplier India, important considerations include composition accuracy, prolonged-release characteristics, product authorization, packaging, batch traceability, shelf life and applicable supply terms.

2. Key Ingredient

Composition:

Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg

Glimepiride 1 mg: Glimepiride belongs to the sulfonylurea class of antidiabetic medicines. It stimulates pancreatic beta cells to release insulin, helping lower elevated blood glucose levels. Hypoglycaemia is an important risk, especially when meals are skipped or other glucose-lowering medicines are used.

Pioglitazone 15 mg: Pioglitazone belongs to the thiazolidinedione class. It activates peroxisome proliferator-activated receptor gamma (PPAR-γ), helping improve insulin sensitivity in tissues such as muscle and adipose tissue. It is associated with important precautions, including fluid retention and worsening heart failure in susceptible patients.

Metformin 500 mg prolonged release: Metformin is a biguanide that primarily reduces glucose production in the liver and improves insulin sensitivity. Its prolonged-release formulation is designed to release the medicine over an extended period. The exact release characteristics and instructions for use must be confirmed against the approved product information.

Businesses researching a Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR pharmaceutical company India should review product composition, approved labelling, release formulation, manufacturing source and applicable quality documentation.

Companies seeking a Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR medicine manufacturer India should verify product authorization, manufacturing details, batch documentation and relevant regulatory requirements before entering into a commercial arrangement.

3. Key Benefits

Three complementary mechanisms: Combines insulin secretion stimulation, improved insulin sensitivity and reduced hepatic glucose production.

Type 2 diabetes management: May support glycaemic control in appropriately selected adults when prescribed by a qualified healthcare professional.

Different pharmacological classes: Each active ingredient works through a distinct mechanism involved in glucose regulation.

Oral combination formulation: Provides a Tablet-based option when the prescriber considers all three ingredients appropriate.

Individualized treatment planning: May be considered when a clinician determines that combination therapy is suitable for the patient’s clinical needs.

Support for comprehensive diabetes care: Treatment can form part of a wider plan involving dietary management, physical activity and regular monitoring.

The combination is not appropriate for every patient. Glimepiride can cause hypoglycaemia, Pioglitazone may cause fluid retention and worsen heart failure, and Metformin requires assessment of kidney function. Treatment decisions should consider the patient’s medical history, current medicines and approved prescribing information.

Pharmaceutical buyers searching for a Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR supplier India should verify current product availability, composition, approved release formulation, batch information and shelf life.

A Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR Tablet wholesaler and distributor India enquiry may include product availability, distribution eligibility, order requirements, delivery arrangements and applicable commercial terms.

Businesses looking for a Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR bulk supplier India should request formal product and supply information, including packaging specifications, storage conditions, expiry details and batch traceability.

A Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR pharmaceutical distributor India should verify product authorization, follow appropriate storage and distribution practices, and use approved product information when communicating with healthcare professionals.

4. How Does It Work?

The three active ingredients support blood glucose management through different mechanisms.

Glimepiride stimulates insulin secretion from pancreatic beta cells. It acts on sulfonylurea receptors associated with ATP-sensitive potassium channels, leading to cellular changes that promote insulin release. This action can lower blood glucose but may also cause hypoglycaemia.

Pioglitazone activates PPAR-γ receptors involved in regulating glucose and lipid Metabolism. It improves insulin sensitivity in peripheral tissues and helps the body respond more effectively to insulin. It does not work by directly stimulating insulin release.

Metformin prolonged release primarily reduces glucose production in the liver and improves insulin sensitivity. The prolonged-release formulation is designed to release the medicine over an extended period, according to its approved formulation characteristics.

Together, the ingredients address different aspects of glucose regulation. However, the combination requires careful patient selection because of hypoglycaemia risk, Pioglitazone-associated fluid retention and heart failure concerns, and Metformin-related precautions involving kidney function and lactic acidosis.

5. Directions for Use

Dosage: Take only as prescribed by a doctor. The appropriate regimen depends on the patient’s clinical condition, previous treatment, blood glucose control and other medicines.

Administration: Follow the approved product label and the prescriber’s instructions for this bilayered formulation.

With food: Metformin prolonged-release formulations are commonly taken with food. Confirm the correct timing for this particular product using its approved information.

Swallowing: Do not crush, chew or split the Tablet unless the approved product information specifically permits it, as this may affect its release characteristics.

Regular timing: Follow the prescribed schedule consistently and do not adjust the dose independently.

Blood glucose monitoring: Monitor blood glucose as recommended by the treating clinician.

Missed dose: Follow the approved patient information or ask a doctor or pharmacist. Do not take a double dose to compensate for a missed dose.

Meal planning: Avoid skipping meals because Glimepiride may cause low blood glucose.

Kidney function: Kidney function should be assessed before and during Metformin treatment as clinically indicated.

Heart health: Inform the prescriber about heart failure, swelling, unexplained weight gain or significant cardiac disease before starting treatment.

Lifestyle measures: Continue recommended dietary measures, physical activity and regular clinical follow-up.

The suitability of this triple combination must be assessed by a qualified healthcare professional. Do not start, stop or change treatment without medical advice.

6. Possible Side Effects

Possible side effects associated with the three ingredients include:

Hypoglycaemia: Low blood glucose, which may cause sweating, shakiness, hunger, dizziness, headache, confusion or weakness.

Gastrointestinal symptoms: Nausea, diarrhoea, abdominal discomfort, bloating or reduced appetite, particularly with Metformin.

Oedema or fluid retention: Swelling of the ankles or legs may occur with Pioglitazone.

Weight gain: Weight changes may occur, particularly with Pioglitazone and some combination treatment plans.

Headache or dizziness: These symptoms may occur in some patients.

Vitamin B12 reduction: Long-term Metformin use may reduce vitamin B12 levels.

Important warning signs:

Heart failure symptoms: New or worsening shortness of breath, rapid weight gain or increasing swelling require prompt medical assessment. Severe breathing difficulty requires emergency care.

Severe hypoglycaemia: Confusion, seizures or loss of consciousness require emergency medical attention.

Possible lactic acidosis: Unusual severe weakness, muscle pain, breathing difficulty, unusual sleepiness or feeling seriously unwell require urgent assessment, particularly in people with kidney impairment, severe dehydration or acute illness.

Liver-related symptoms: Yellowing of the skin or eyes, dark urine or persistent unexplained nausea should be assessed promptly.

Allergic reaction: Facial or throat swelling or difficulty breathing requires emergency care.

This list is not exhaustive. Report persistent or concerning symptoms to a healthcare professional.

7. Safety Information

Medical supervision: Use only under the guidance of a qualified healthcare professional.

Type 1 diabetes: This combination is not intended to treat type 1 diabetes or diabetic ketoacidosis.

Hypoglycaemia: The risk is associated particularly with Glimepiride and may increase when meals are skipped, during fasting, with alcohol or with interacting medicines.

Heart failure: Pioglitazone may cause fluid retention and can worsen or precipitate heart failure. Patients with current or previous heart failure must be assessed carefully, and applicable contraindications in the approved product information must be followed.

Kidney function: Metformin is unsuitable in severe renal impairment. Kidney function should be assessed before treatment and monitored as recommended by the clinician.

Liver health: Inform the prescriber about liver disease. Pioglitazone and Metformin require appropriate clinical assessment in patients with relevant liver conditions.

Dehydration and acute illness: Severe dehydration, serious infection, reduced oxygen supply or other acute illness may increase Metformin-related risks. Seek medical advice promptly.

Bladder cancer history: Pioglitazone requires careful review in patients with a history of bladder cancer or unexplained blood in the urine. Follow the approved product information.

Fracture risk: Pioglitazone may increase fracture risk in some patients, particularly with long-term use.

Surgery and contrast procedures: Inform the healthcare team about Metformin before surgery or procedures involving iodinated contrast. Temporary interruption may be required in some circumstances under medical guidance.

Pregnancy: Consult a doctor before use during pregnancy or when planning pregnancy. The clinician should reassess the most appropriate diabetes treatment.

Breastfeeding: Seek medical advice before use while breastfeeding.

Drug interactions: Inform the doctor about all prescription medicines, over-the-counter products and supplements, including insulin and other glucose-lowering medicines.

Alcohol: Discuss alcohol use with the prescriber and avoid excessive intake because it may increase treatment-related risks.

Storage: Store in the original packaging according to the approved product label, protected from excessive heat and moisture and out of children’s reach.

This information is educational and does not replace approved prescribing information or individualized medical advice. Verify all product-specific warnings against the approved label before publication.

8. B2B Pharmaceutical Business Enquiries

CardianCare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business partners. Pharmaceutical procurement teams, distributors, wholesalers and other eligible business partners can contact the company to enquire about current product availability and applicable commercial arrangements.

Businesses researching a Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR PCD pharma franchise India opportunity should confirm whether the product is included in a current programme. Product eligibility, territory availability, partner requirements and commercial terms require direct verification.

For a Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR Tablets PCD pharma franchise enquiry, prospective partners can ask about eligible products, order requirements, distribution conditions and approved promotional materials.

Companies exploring a Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR Tablet PCD franchise should verify programme availability and applicable terms before making investment or promotional commitments.

Businesses researching Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR third party manufacturing India should first confirm whether the proposed company offers these services. If applicable, due diligence should include manufacturing permissions, product approvals, applicable GMP compliance, formulation specifications and quality agreements.

A Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR Tablet third party manufacturer India enquiry should cover manufacturing authorization, release-formulation requirements, quality control procedures, packaging specifications, batch documentation and contractual responsibilities.

Companies investigating Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR contract manufacturing India should confirm service availability and discuss technical documentation, formulation specifications, regulatory responsibilities, quality agreements, minimum batch quantities and commercial feasibility with the proposed partner.

Visit & contact CardianCare regarding current product availability and applicable pharmaceutical business arrangements. PCD franchise, distribution and manufacturing services should be verified directly with the company before being represented as available.

9. For More Information

For more information about GLISOT 1-PM Tablet (Bilayered) – Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg PR, click here

Frequently Asked Questions

It may be prescribed to help manage blood glucose levels in adults with type 2 diabetes when all three active ingredients are considered appropriate by a qualified healthcare professional. It should be used alongside recommended dietary measures, physical activity and monitoring.

The stated composition is Glimepiride 1 mg, Pioglitazone 15 mg and Metformin 500 mg prolonged release. Confirm the exact release characteristics and administration instructions against the approved product label.

Glimepiride stimulates insulin release, Pioglitazone improves insulin sensitivity through PPAR-γ activation, and Metformin primarily reduces glucose production in the liver and improves insulin sensitivity.

It combines three complementary glucose-lowering mechanisms in an oral formulation for selected adults with type 2 diabetes. suitability depends on clinical assessment, other medicines and the risks associated with each ingredient.

Take it exactly as prescribed and follow the approved product instructions. Metformin prolonged-release formulations are commonly taken with food. Do not crush, chew or split the Tablet unless the approved information specifically permits it.

Possible effects include hypoglycaemia, gastrointestinal discomfort, swelling, weight gain, headache and vitamin B12 reduction with long-term Metformin use. New or worsening breathlessness, marked swelling or symptoms of severe hypoglycaemia require prompt medical attention.

People with heart failure, kidney or liver disease, a history of bladder cancer, significant swelling, dehydration or other serious illnesses need careful clinical assessment. Pregnancy, breastfeeding and concurrent medicines should also be discussed with the prescriber.

Glimepiride stimulates insulin secretion, Pioglitazone improves insulin sensitivity through a different receptor pathway, and Metformin reduces hepatic glucose production. Their complementary mechanisms do not mean the combination is suitable for every patient.

Store it in its original packaging according to the approved product label, protect it from excessive heat and moisture, and keep it out of children's reach.

Eligible pharmaceutical businesses can visit www.CardianCare.com to enquire about current product availability and applicable commercial arrangements. Distribution, PCD franchise and manufacturing services must be confirmed directly with the company.

Reviews

There are no reviews yet.

Be the first to review “Glimepiride + Pioglitazone + Metformin PCD Pharma Franchise”

Your email address will not be published. Required fields are marked *

Enquiry Now
close slider

    Drop us a Line